Can Ozempic Cause Vision Loss? What the NAION Research Shows in 2026

If your feeds are full of posts about Ozempic and eyesight, there is a real study trail behind them — and a real regulatory gap. The condition at the center of it is NAION, a rare injury to the optic nerve. Here is what the evidence actually shows, with the numbers.

What is NAION?

Non-arteritic anterior ischemic optic neuropathy (NAION) happens when blood flow to the front of the optic nerve drops and the nerve is damaged. It typically causes abrupt, painless vision loss in one eye, and the damage can be permanent. It is sometimes described as a stroke of the eye. It is rare, which is exactly why it took large studies to detect a link.

How did the Ozempic–eyesight link start?

In July 2024, researchers at Mass Eye and Ear published a study in JAMA Ophthalmology that looked back at patients seen in their neuro-ophthalmology clinic. Patients with type 2 diabetes who were prescribed semaglutide were diagnosed with NAION about 4 times as often as those who were not, and patients with overweight or obesity about 7.6 times as often. The authors cautioned that an observational study cannot prove the drug caused the condition — but the finding launched the wave of research that followed.

What did the 2026 veterans studies find?

Two large U.S. veterans studies published this year are the strongest evidence so far, because they compared GLP-1 users with people starting a different class of diabetes drug (SGLT2 inhibitors) rather than with no treatment at all.

• Semaglutide specifically (JAMA Ophthalmology, February 2026): among 102,361 veterans with type 2 diabetes, people who started semaglutide had 2.33 times the risk of NAION compared with people who started an SGLT2 inhibitor. In absolute terms, that is 0.29% versus 0.13%.
• GLP-1 drugs as a class (JAMA Network Open, April 2026): among 588,168 veterans, NAION occurred in 39 per 10,000 GLP-1 users over three years versus 29 per 10,000 SGLT2 users — roughly one extra case per 1,000 people over three years.

Both studies were in older, mostly male veterans with diabetes, and both are observational. But they point in the same direction: a small increase in a rare event.

How big is the risk, really?

Small. Europe's medicines regulator classifies NAION as a very rare side effect of semaglutide — one that may affect up to 1 in 10,000 people taking it. The veterans studies suggest a somewhat larger excess in older adults with diabetes, but in every study the absolute risk stays well under 1%. Whether that trade-off makes sense for you is a decision to make with a clinician, and it is a more important conversation if you have had optic-nerve or eye-circulation problems before.

Why do Europe and the UK warn about NAION when the U.S. label doesn't?

In June 2025, the European Medicines Agency's safety committee concluded that NAION is a very rare side effect of semaglutide and that treatment should be stopped if NAION is confirmed. The UK's MHRA followed with its own safety update in February 2026, telling clinicians to refer patients with sudden vision loss urgently to an ophthalmologist.

In the United States, the current Wegovy prescribing information (revised June 2026) does not list NAION. Its eye-related warning covers diabetic retinopathy complications in people with type 2 diabetes. Regulators weigh evidence on their own timelines, and a missing label warning is not proof that a risk is absent — which is why this story keeps resurfacing in U.S. feeds.

Do Mounjaro and Zepbound carry the same risk?

Less is known. Most NAION research has focused on semaglutide, which has been on the market longer. The April 2026 veterans study found the association for GLP-1 receptor agonists as a class, but it was not designed to single out tirzepatide. Treat the tirzepatide question as open, not settled in either direction.

What eye symptoms mean you should get help today?

• Sudden loss of vision or blurring in one eye, even without pain.
• A dark, dim, or missing patch in part of what you see.
• Any rapid worsening of your eyesight while taking a GLP-1.

If any of these happen, call your prescriber and get an urgent eye exam the same day. Europe's regulator advises stopping semaglutide if NAION is confirmed — a decision your clinician should make with you.

Should you stop your GLP-1 because of this?

Not on your own. Stopping abruptly has its own costs, including weight regain and loss of blood-sugar control. The better move is a conversation: tell your clinician about any history of eye or optic-nerve problems, ask whether a baseline eye exam makes sense for you, and know the warning signs above.